v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development $ 20,714 $ 21,862
Research and development - related party 479  
General and administrative 15,409 10,624
Total operating expenses 36,602 32,486
Loss from operations (36,602) (32,486)
Interest income 1,314 1,124
Other expense, net (190) (114)
Net loss $ (35,478) $ (31,476)
Net loss per share - basic $ (12.17) $ (24.92)
Net loss per share - diluted $ (12.17) $ (24.92)
Weighted average shares and pre-funded warrants outstanding, basic 2,915,894 1,262,840
Weighted average shares and pre-funded warrants outstanding, diluted 2,915,894 1,262,840
Comprehensive Loss:    
Net loss $ (35,478) $ (31,476)
Unrealized gain on available-for-sale securities 7 4
Comprehensive loss $ (35,471) $ (31,472)